Clinical Trial Search

Primary: Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment — 5; 4; NA Days

Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Primary: Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes) — 7.4; 6.7; 8.5; 7.5 units on a scale

Primary: Change in Basophil Surface IgE — -95; -10 percentage of basophil surface IgE

Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects

Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…

Primary: Mean Change From Baseline for Mean Reflective Total Nasal Symptom Score (rTNSS) — -2.95; -3.13; -1.98 score on a scale

Primary: Extent of Urticaria/Erythema Score (Physician Assessment) — 1.91; 1.74; 1.53; 1.12 units on a scale

Primary: D. Farinae Specific IgG4 Change From Baseline to End of Treatment — 0.473; -0.01 mg antibody/ml

Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…

Primary: Proportion of Participants With Agreement of Perception of Cooling Sensation — 0.99 Proportion of participants

Primary: Change of Patient Rated Pruritus Score — -1.61; -1.50 score on a scale

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale

Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005

Primary: Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) — 7.70; 6.88; 6.41; 8.46…

Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002

Primary: Daily Combined Score (DCS) — -4.41; -1.61 DCS (daily combined score)

Primary: Baseline Adjusted Area Under the Curve (AUC) of Minimal Cross-Sectional Area (MCA) of Nasal Cavity by Acoustic Rhinometry — -0.682; -0.504; -0.550 square centimeter*hour…

Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532

Primary: Total Nasal Symptom Score (TNSS) Area Under the Curve (AUC) — 2.46; 2.81; 3.66; 3.10 Total Nasal Symptom Score * Hour — p=0.314

Primary: The the Size of the 8 Late-phase Skin Response — 54; 0 percentage decline from NAC-1

Primary: Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) — 6.70; 6.22; 8.46 score on a…

Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days — 17.98; 18.48; -1.97; -3.53 Scores on a scale — p=<0.001

Primary: Fold Change From Baseline at Hour 8 in Interleukin 5 (IL-5) Concentration — 26.94; 6.70; 1.86 Fold Change — p=0.002

Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…

Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)

Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants

Primary: Pruritus as Assessed by the VAS Score — 11.5; 25.4; 46.0 mm

Primary: Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation. — 0.69; 2.27 units on a scale